articleTop 1% cited

Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors

The Journal of Urology · 2016 · Vol. 197(2S) · pp. 180–3

Álvaro Morales✉(Queen's University)David Eidinger(Queen's University)Andrew W. Bruce(Queen's University)

Abstract

Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin. The pattern of recurrence in 9 patients has been altered favorably. Although the findings are still preliminary they appear to hold promise of a new therapeutic approach to the treatment of a group of neoplasms for which effective therapy is still lacking.

Bladder and Urothelial Cancer Treatments Cancer Research and Treatments Urological Disorders and TreatmentsMedicineBacillus (shape)Bladder tumorUrinary bladderUrologySurgeryPathologyInternal medicineBladder cancerCancer

MeSH terms

Antineoplastic Agents, ImmunologicalAdministration, IntravesicalAgedAged, 80 and overBCG VaccineUrinary Bladder NeoplasmsCarcinoma, Transitional CellCystoscopyFemaleHumansInjections, IntradermalMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective Studies

Citations

1,534

FWCI

81.28

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY